Eli Lilly (LLY), explained in plain English

🏥 Health & Medicine

Eli Lilly

(LLY ↗)

lilly.com ↗

Eli Lilly's weight-loss and diabetes shots — Mounjaro and Zepbound — are growing so fast they've remade a 150-year-old drugmaker. The questions: can it make enough, and what happens when rivals and patents close in?

Updated · Q1 2026 · April 2026

Chapters

~17

Min read

~$72B / yr revenue · ~50K employees · public since 1952

🌶️🌶️

Spice: Jalapeño (3/5)

More filled = spicier (more aggressive), not "better." Tap a row to see what it means.

What is spice?

Your progress

0 of 6

Growth

~4 min

The Shot Heard Round the World

Two weight-loss shots are growing a 150-year-old drugmaker faster than most startups.

›

Financial Health

~4 min

Minting Money, Building Factories

Lilly's profit grew 141%. It's spending the windfall as fast as it can — on factories.

›

Moat

~3 min

Patents, Pills, and a Two-Horse Race

Only two companies really matter in weight-loss drugs. Lilly is working hard to keep it that way.

Lilly bet on weight-loss science and pre-built factories years before the boom was obvious.

›

Behind the Numbers

~2 min

The Story Behind the Numbers

The income statement says *what* happened. The company's own write-up says *why*.

›

Risk

~2 min

One Molecule, Two Threats

Two-thirds of Lilly rides on a single molecule. And its price is already falling.

↻ Next update · Aug 6

est. Aug 6, 2026 · Q2 2026 · Lilly IR ↗

›

✦ Reader takes on Eli Lilly

0 comments

Drop your read. See how others are calling this brief.

No one's weighed in yet. Be the first.

↗ Share Eli Lilly

↻ The read keeps updating

You're reading the 6 opening chapters. After that, every time Lilly files a new report, the chapters get updated here.